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Growth arrest-specific protein 6 (GAS6) is a soluble agonist of the TYRO3, AXL, MERTK (TAM) family of receptor tyrosine kinases
identified to have anti-inflammatory, neuroprotective, andpromyelinating properties. During experimental autoimmune encephalomy-
elitis (EAE),wild-type (WT)micedemonstrate a significant inductionofGas6,Axl, andMertkbutnotPros1orTyro3mRNA.We tested the
hypothesis that intracerebroventricular delivery of GAS6 directly into the CNS of WTmice during myelin oligodendrocyte glycoprotein
(MOG)-induced EAE would improve the clinical course of disease relative to artificial CSF (ACSF)-treated mice. GAS6 did not delay
disease onset, but significantly reduced the clinical scores during peak and chronic EAE. Mice receiving GAS6 for 28 d had preserved
SMI31neurofilament immunoreactivity, significantly fewer SMI32 axonal swellings and spheroids and less demyelination relative to
ACSF-treatedmice. Alternate-day subcutaneous IFN injection did not enhance GAS6 treatment effectiveness.Gas6/mice sensitized
withMOG35-55 peptide exhibit higher clinical scores during late peak to early chronic disease,with significantly increased SMI32
 axonal
swellings and Iba1microglia/macrophages, enhanced expression of several proinflammatorymRNAmolecules, anddecreased expres-
sion of early oligodendrocyte maturation markers relative to WT mouse spinal cords with scores for 8 consecutive days. During acute
EAE, flow cytometry showed significantlymoremacrophages but not T-cell infiltrates inGas6/ spinal cords thanWTspinal cords. Our
data are consistentwithGAS6beingprotectiveduringEAEbydampening the inflammatory response, therebypreservingaxonal integrity
and myelination.
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Introduction
Growth arrest-specific protein 6 (GAS6) is a major vitamin
K-dependent, -carboxylated, secreted growth factor that func-
tions in cell survival, adhesion, chemotaxis, mitogenesis, and cell
growth. GAS6 is the sole ligand for AXL, one of threemembers of
the TYRO3, AXL andMERTK (TAM) family of receptor tyrosine
kinases that are activated by GAS6 (Stitt et al., 1995; Varnum et
al., 1995; Nagata et al., 1996). The relative affinity of Gas6 for its
receptors is AXLTYRO3MERTK (Nagata et al., 1996; Sasaki
et al., 2006). Unlike AXL, TYRO3 and MERTK are also activated
by PROS1, another vitamin K-dependent protein that shares
46% homology with GAS6. PROS1 has an important role in
blood coagulation, a role that does not involve TAM receptors or
GAS6. Deletion of Pros1 results in embryonic lethality, whereas
Gas6/mice are viable (Prasad et al., 2006; Rothlin and Lemke,
2010).
GAS6 is expressed at high levels in the brain during early
development and continues to be expressed throughout adult-
hood (Prieto et al., 1999). TAM receptors are expressed in astro-
cytes, neurons, oligodendrocytes, and microglia/macrophages.
The extracellular domain exhibits amino acid similarity to neural
cell adhesion molecules (Prieto et al., 2000).
A study ofGas6/mice during cuprizone-induced demyeli-
nation and recovery determined that, relative to C57BL/6J wild-
type (WT) mice, Gas6/ mice had increased oligodendrocyte
loss, delayed remyelination, and prolonged microglial activation
3 weeks after the removal of cuprizone from the diet (Binder et
al., 2008). This study is consistent with our findings that, relative
to WT mice receiving saline, administration of GAS6 into the
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corpus callosum after cuprizone intoxication enhanced remyeli-
nation and recovery (Tsiperson et al., 2010).
In brain homogenates prepared from established multiple
sclerosis (MS) lesions, levels of cleaved soluble AXL, membrane-
bound MERTK, and soluble MERTK were all significantly ele-
vated (Weinger et al., 2009). Unlike normal brain tissue, in which
GAS6 was positively correlated with soluble AXL and MERTK,
there was a negative correlation between GAS6 and soluble AXL
andMERTK in establishedMS lesions. Soluble AXL andMERTK
can act as decoy receptors to block GAS6 binding to membrane-
bound receptors (Sather et al., 2007; Weinger et al., 2009). Axl/
mice are more severely affected during both cuprizone intoxica-
tion and recovery and during acute myelin oligodendrocyte
glycoprotein (MOG)-induced experimental autoimmune en-
cephalomyelitis (EAE) (Hoehn et al., 2008; Weinger et al., 2011).
These data suggest that, in MS lesions and mouse models, dys-
regulation of protective GAS6 receptor signaling may prolong
lesion activity and strongly support a role for GAS6/TAM signal-
ing in the mature nervous system.
In this study, we sought to characterize the role of GAS6 in the
preservation of CNS function and recovery after MOG35-55-
induced EAE, a model of autoimmunity that shares several clin-
ical and pathologic features with MS. Induction of EAE disrupts
the blood–brain barrier resulting in infiltration of T cells and
monocytes, increased inflammation, expression of proinflamma-
tory molecules, demyelination, and axonal damage. We hypoth-
esized that GAS6 administration during EAE would decrease
disease severity, enhance recovery, and reduce long-term axonal
damage and, conversely, that loss of GAS6 signaling would in-
crease disease severity.
Materials andMethods
Mice
C57BL/6J WT were obtained from The Jackson Laboratory and bred
in-house. Gas6/mice were obtained from Dr. Pablo García de Frutos
(Institute of Biomedical Research of Barcelona). All mice were exten-
sively backcrossed on WT C57BL/6J mice by the Shafit-Zagardo labora-
tory andWTC57BL/6J mice were used as controls. All experiments were
performed with 8- to 12-week-old male and female mice. All animal
procedures were approved by the Institute of Animal Care andUseCom-
mittee at theAlbert EinsteinCollege ofMedicine in complete compliance
with the National Institutes of Health’s Guide for Care and Use of Labo-
ratory Animals.
MOG-induced EAE: active induction of EAE
C57BL/6J and Gas6/ mice were immunized with MOG35-55 peptide.
MOG35-55 (3 mg/ml; Peptides International) was emulsified in an equal
volume of complete Freund’s adjuvant (CFA). CFA was composed of
Mycobacterium tuberculosis (10 mg/ml; Difco Laboratories) in incom-
plete Freund’s adjuvant (Difco Laboratories). Mice were anesthetized
with isoflurane and 100 l of emulsion was injected subcutaneously on
each flank (200l total/mouse) on day 0. In addition, 200l of pertussis
toxin (Ptx, 2.5 g/ml; List Biological Laboratories) was injected intra-
peritoneally on days 0 and 2. Mice were monitored and graded daily for
clinical symptoms of disease as follows: 0 no disease; 1 limp tail; 2
limp tail and hindlimb weakness; 3 hindlimb paralysis; 4 hindlimb
and front limb paralysis; and 5  moribund. Mice that did not present
with clinical scores were not included in analysis (2% of total).
Cannulation and micro-osmotic pump implants
Cannulation. Alzet cannulae (Brain Infusion Kit 3) were prepared the
night before surgery by sterilely attaching an 1.5 cm length of tubing,
filling the tube with sterile ACSF, and then sealing the end of the tubing.
Mice were anesthetized for the length of the procedure using continuous
administration of isoflurane. The scalp of each mouse was shaved and
ocular lubricant placed in the eyes. The animal was then secured to a
Stoelting stereotaxic frame within a BSL-2 hood. The shaved scalp was
sterilized using Betadine (Purdue Products) followed by isopropanol
wipes. A small incision was made using a sterile #20 scalpel blade; the
revealed area of the skull was cleaned using a sterile cotton-tipped appli-
cator. The stereotaxic frame was used to place each cannula at the coor-
dinates 0.4 mm posterior to bregma, 1 mm lateral right. Once these
coordinates were identified, a small hole was drilled in the skull using a
sterilized Dremel 108 engraving cutter (Robert Bosch) and the tubing
attached to the cannula was threaded under the skin on the left side of the
mouse. The cannula was then positioned 2.5mmbelow the surface of the
skull and glued into place using Loctite Prism 454 adhesive followed by a
layer of fast curing orthodontic resin (Ortho-Jet; Lang Dental). After
surgery, mice were immediately placed on a warm pad until fully recov-
ered from anesthesia and then allowed to heal for 3 weeks before sensi-
tization with MOG.
Pump insertion. Micro-osmotic pumps (Alzet model 1104, 0.11 l/h,
28 d) were attached 6 d after the second Ptx injection. Two days before
the surgery, pumps were sterilely loaded with active (Tsou et al., 2014),
full-length human -carboxylated GAS6 (4 g/ml; Amgen) diluted in
ACSF or ACSF alone. In a previous study using GAS6 osmotic pumps for
cuprizone recovery, we determined that 400 ng/ml to 40g/mlGAS6was
effective, but 4g/ml was the optimal dose (Tsiperson et al., 2010). After
loading, pumps were placed in sterile PBS at 37°C to equilibrate and
begin pumping. Again, allmicewere anesthetized using isoflurane for the
length of the procedure and ocular lubricant was used to prevent blind-
ness in the animals. A small area on the back of themice corresponding to
the area where the cannula tubing was placed under the skin was shaved
and sterilized as above. A 0.5 cm incision was made using a #10 scalpel
blade and space for the pump under the skin was made using a sterilized
hemostat. The pump was then inserted under the skin; the sealed end of
the cannula tubing was removed and the tubing was attached to the
pump. The incisionwas closed usingVet-bond tissue adhesive (3M). The
mice were placed on a warm pad, provided with gel food, and allowed to
recover fromanesthesia. After surgery, themiceweremonitored daily. As
a result of the length of the tubing from the cannula to the pump, mice
began to receive the contents of each pump 2–3 d after attachment.
IFN treatment
Mice were injected subcutaneously with 3  104 units of IFN/Betase-
ron purchased fromBayer every other day, beginning 7 d after the second
Ptx injection until the conclusion of the experiment.
Spinal cord dissection and tissue preparation
Mice were anesthetized with isoflurane U.S.P. (ISOTHESIA, Butler
Schein) and killed by total body perfusion with 4% paraformaldehyde
(Fisher Scientific) or 1 PBS, pH 7.3. Spinal cords were removed and
dissected into cervical, thoracic, and lumbar regions. Sections were
placed in fixative for immunohistochemistry or RNAlater (Life Technol-
ogies) for RNA isolation.
Antibodies (Abs), immunohistochemistry, immunofluorescent
staining, and stains
Myelin basic protein (MBP) monoclonal antibody (mAb) SMI99 (1:
2000) and neurofilament mAb SMI32 (1:20 000) and mAb SMI31 (1:
10 000) were purchased from Covance. Iba1 polyclonal Ab (1:400) was
purchased from Wako Chemicals. CD3 was purchased from Dako.
Paraformaldehyde-fixed tissues were stored overnight at 4°C, transferred
to 25% sucrose, and paraffin embedded. Frozen sections were prepared
from the paraformaldehyde-fixed sections. Paraffin-embedded sections
(5 M) were immersed in xylene and rehydrated through descending
alcohols and brought to 1 Tris buffered saline, pH 7.4 (1 TBS). An-
tigen retrieval was achieved bymicrowaving the slides in boiling distilled
water for 7 min on high power and 7 min on power 7. Sections were
incubated for 15 min with 1 TBS containing 0.25% Triton X-100.
Exogenous peroxidase was quenched using 3%hydrogen peroxide in 1
TBS for 15 min at room temperature. Sections were blocked with a 1 h
incubation in 5% goat serum and 5% nonfat dry milk in 1 TBS and
incubatedwithAbs diluted in 5%nonfat drymilk in 1TBS overnight at
4°C. Sections were washed 3 times in 1 TBS and incubated with sec-
ondaryAb followed by incubationwith the appropriateVecta staining kit
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(Vector Laboratories) and visualized by diaminobenzidine (DAB;
Sigma). Sections were visualized on a Leica Leitz DRMBmicroscopewith
an Olympus DP12 camera. For immunofluorescent staining, all second-
ary antibodies were Alexa Fluor-conjugated isotype specific purchased
from Fisher Scientific. Fluorescent images were captured using anOlym-
pus IX81 microscope with a Cooke Sensicam QE.
Quantification of Iba1microglia/macrophage
inflammatory score
Before quantification, slides were blinded and at least three sections of
lumbar spinal cord for each animal were assessed by two individuals; the
number of animals used for each experiment is indicated in the figure
legends. Iba1 cells in cross-sectional spinal cord were scored on a 1–4
inflammatory scale where 1  mild inflammation at lesions, 2  mod-
erate inflammation at lesions, 3  severe inflammation at lesions, and
4 very severe inflammation involving 50% or more of the spinal cord
(Tsiperson et al., 2013). Mann–Whitney U test was used to evaluate
statistical significance.
Scoring of demyelination after MBP immunohistochemistry
(DAB visualization)
Before quantification, slide identity was masked to the reviewer and at
least three sections of lumbar spinal cord/specimen were assessed by two
individuals; the number of animals used for each experiment is indicated
in the figure legends. A score of 0 is the equivalent of MBP immunore-
activity observed in naive ventral spinal cord; a score of 0 was not ob-
served in any of the examined EAE sections. A score of 1  mild
demyelination, 2moderate demyelination, 3 severe demyelination,
and 4 very severe involving50% of white matter. Mann–WhitneyU
test was used to evaluate statistical significance.
Quantification of percentage demyelination after
immunofluorescent staining
The extent of demyelination was calculated in slides stained for MBP
and DAPI. The percentage of the demyelinated area relative to the
total white matter area within the lumbar spinal was determined by
imaging cross sections at 4. The total area of demyelination and
myelination was calculated in ImageJ and converted to percentage
demyelination (Tsiperson et al., 2013). Student’s t test was used to
evaluate statistical significance.
Quantitative real-time RT-PCR
Quantitative real-time RT-PCR (qRT-PCR) was performed using total
RNA extracted from lumbar spinal cord using Qiazol Reagent with
RNeasy kit (Qiagen). cDNA was synthesized using 500 ng of total RNA
with the iScript cDNA synthesis kit (Bio-Rad). Gene expression was an-
alyzed using iTaq Universal SYBR Green Supermix (Bio-Rad) on a
StepOne Plus Real-Time PCR System (Life Sciences). Samples were run
in duplicate for each of the genes listed in Table 1 and normalized using
the geometric mean of -actin, HPRT, and GAPDH with a WT sample
set as a reference. Fold induction was calculated as 2Ct (Livak and
Schmittgen, 2001). Melting curves were determined for every sample to
ensure specificity of the amplicon.
Flow cytometry
To evaluate populations of immune cell subsets from Gas6/ and WT
mice, single cell suspensions were prepared and flow cytometry was per-
formed. Mice having clinical scores for 3–4 d were anesthetized and
perfused with 20 ml of cold PBS and spinal cords were isolated and
injectedwith 3ml of digestion buffer consisting of serum-free RPMI1640
containing Roche Liberase Grade TL 0.3 Wunsch units/ml and 300
Kunitz units DNase I/ml using a syringe tipped with a 26 3/8 gauge
needle. The tissue was cut into small pieces and incubated at 37°C with
5%CO2 for 30min. Using the rubber plunger from a 3ml syringe, spinal
cords were dissociated through a 70 micron cell strainer (BD Falcon)
submerged in digestion buffer. The single-cell suspension was centri-
fuged at 300 g for 10 min at 4°C and washed twice with a large volume
of PBS and filtered one additional time using a 70 micron cell strainer.
Cells were then washed with FACS buffer (PBS 2% fetal calf serum
0.05% sodium azide) and blocked with mouse anti-FcRII/III (clone
2.4G2) for 30 min at 23°C and surface stained with anti-CD68 (PerCP/
Cy5.5 clone FA-11) and anti-CD25 (PE/Cy7 clone PC61) purchased
from BioLegend, anti-CD45 (PE clone 30F11), and anti-CD11c (APC
clone N418) purchased from eBioscience, anti-CD4 (APC-H7 clone
GK1.5), anti-CD11b (Alexa Fluor 700 clone M1/70), anti-CD45R/B220
(PE-Cy5 clone RA3–6B2), and anti-CD44 (FITC clone IM7) purchased
from BD Pharmingen. For intracellular transcription factor staining,
cells were fixed and permeabilized using the eBioscience FoxP3 staining
kit according to the manufacturer’s instructions and stained with anti-
FoxP3 (eFluor 450 clone FJK-16s) and anti-RORt (PE-CF594 clone
Q31–378) purchased from eBioscience. Samples were acquired on an
LSR II flow cytometer using FACSDiva software (BD Biosciences) and
analysis was performed using FlowJo software (TreeStar). Compensation
was calculated by FACSDiva software before sample acquisition using
anti-mouse Ig,  or anti-rat/hamster Ig,  CompBead Plus (BD Biosci-
ences) compensation beads singly stained with the appropriate
fluorophore-conjugated antibodies. For the identification of leukocytes,
aggregates were excluded from analysis by gating on cells with equivalent
FSC-H/FSC-A and low SSC-W/SSCA profiles. Activated T cells were
identified by gating on CD4 cells expressing the activation markers
CD25 and CD44. Activated T cells were then identified as Tregs or Th17
by expression of master transcription factors FoxP3 or RORt, respec-
tively. B cells were identified as CD11cCD11bCD45R/B220.Micro-
glia andmacrophages were identified by gating on cells negative for both
CD4 and B220 and positive for CD11b. Macrophages were defined as
CD68CD45hi andmicroglia as CD45 int with variable CD68 expression
reliant on activation state.
Statistical analysis
Statistical analysis was performed with GraphPad Prism version 6.02
software. To analyze significance during EAE, a Mann–Whitney U test
was performed on the clinical indices at each time point. Significance for
relative scales, such as Iba1 and CD3 inflammatory score and MBP rela-
tive demyelination, were assessed for significance by theMann–Whitney
U test. Student’s t test was performed for parametric two-group compar-
isons. Error is represented as SEM.
Table 1. qRT-PCR primer pairs
Gene Forward Reverse
Axl 5	-ATGGCCGACATTGCCAGTG-3	 5	-CGGTAGTAATCCCCGTTGTAGA-3	
-actin 5	-GGCTGTATTCCCCTCCAATCG-3	 5	-CCAGTTGGTAACAATGCCATGT-3	
CCR2 5	-ATCCACGGCATACTATCAACATC-3	 5	-CAAGGCTCACCATCATCGTAG-3	
CD68 5	-TGTCTGATCTTGCTAGGACCG-3	 5	-GAGAGTAACGGCCTTTTTGTGA-3	
CX3CR1 5	-TACCTTGAGGTTAGTGAACGTCA-3	 5	-CGCTCTCGTTTTCCCCATAATC-3	
GAPDH 5	-CGTCCCGTAGACAAAATGGT-3	 5	-TTGATGGCAACAATCTCCAC-3	
HPRT 5	-AGTCCCAGCGTCGTGATTAG-3	 5	-TTTCCAAATCCTCGGCATAATGA-3	
IFN- 5	-TCAAGTGGCATAGATGTGGAAGAA-3	 5	-TGGCTCTGCAGGATTTTCATG-3	
IL-2 5	-CCCAAGCAGGCCACAGAATTGAAA-3	 5	-TGAGTCAAATCCAGAACATGCCGC-3	
IL-4 5	-GGTCTCAACCCCCAGCTAGT-3	 5	-GCCGATGATCTCTCTCAAGTGAT-3	
IL-6 5	-CAGAGGATACCACTACCAACAG-3	 5	-TCTCATTTCCACCACGATTTCCC-3	
IL-10 5	-GCTCTTACTGACTGGCATGAG-3	 5	-CGCAGCTCTAGGAGCATGTG-3	
IL-13 5	-CCTGGCTCTTGCTTGCCTT-3	 5	-GGTCTTGTGTGATGTTGCTCA-3	
IL-17 5	-CAGCAGCGATCATCCCTCAAAG-3	 5	-CAGGACCAGGATCTCTTGCTG-3	
Mertk 5	-CAGGGCCTTTACCAGGGAGA-3	 5	-TGTGTGCTGGATGTGATCTTC-3	
MCP-1 5	-GTATGTCTGGACCCATTCCTTC-3	 5	-GCTGTAGTTTTTGTCACCAAGC-3	
MIP-1 5	-CAGCCAGGTGTCATTTTCCT-3	 5	-AGGCATTCAGTTCCAGGTCA-3	
Olig2 5	-TCCCCAGAACCCGATGATCTT-3	 5	-CGTGGACGAGGACACAGTC-3	
PDGFR 5	-AGAGTTACACGTTTGAGCTGTC-3	 5	-GTCCCTCCACGGTACTCCT-3	
Pros1 5	-CGCTTTCGGGTGCTACTGG-3	 5	-CACTCTCGTTCAAGGTTGCC-3	
RANTES 5	-AGCTGCCCTCACCATCATC-3 5	-CTCGGGTTGGCACACACTT-3	
SOCS1 5	-CTGCGGCTTCTATTGGGGAC-3	 5	-AAAAGGCAGTCGAAGGTCTCG-3	
SOCS3 5	-ATGGTCACCCACAGCAAGTTT-3	 5	-TCCAGTAGAATCCGCTCTCCT-3	
Sox10 5	-GAAGCCCCACATCGACTTCG-3	 5	-GGCAGGTATTGGTCCAGCTC-3	
TGF-1 5	-ACCATGCCAACTTCTGTCTG-3	 5	-CGGGTTGTGTTGGTTGTAGA-3	
TNF- 5	-TGAACTTCGGGGTGATCGGTC-3	 5	-AGCCTTGTCCCTTGAAGAGAAC-3	
Tyro3 5	-GCCTCCAAATTGCCCGTCA-3	 5	-CCAGCACTGGTACATGAGATCA-3	
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Results
Gas6, Axl, andMertk RNA, but not Tyro3 or Pros1mRNA, are
significantly increased inWTmice during EAE
To determine whetherGas6 expression increases during EAE and
might be beneficial for treatment, we sensitized WT mice with
MOG35–55 peptide and examinedGas6, Pros1, and TAM receptor
mRNA expression during EAE relative to naive mice. qRT-PCR
analysis of TAMreceptor and ligand expressionwas performed in
naive WT mice and WT mice with clinical scores for 1, 4, 8, and
20 consecutive days of EAE. Figure 1A illustrates the mean clini-
cal course of theMOG-sensitizedWTmice throughout EAE. The
day one time point represents the first day mice had clinical
scores. Additional time points include peak acute EAE (day 4),
late acute EAE (day 8), and chronic EAE (day 20). Mice with
clinical scores for 20 consecutive days (day 30 EAE) had a sig-
nificant reduction in scores relative to mice with clinical scores
for 4 consecutive days (p
 0.05), indicating that significant re-
covery had taken place over that time. Figure 1B shows thatMertk
was significantly increased in mice with clinical scores for 4 d
(p 
 0.001) and 8 d (p 
 0.05), correlating with the influx in
monocyte/macrophages and glial activation. Figure 1C shows
that, relative to naive mice, there was a significant increase in
Gas6 mRNA in mice with scores for 8 consecutive days (p 

0.001). Although not significant by one-way ANOVA, Axl ex-
pression increased 1.9-fold and 2.6-fold after 1 and 4 d sick, re-
spectively (Fig. 1D). Axl expression was significantly elevated in
mice sick for 8 d relative to naive with a 7.5 0.42-fold increase
(p 
 0.0001, one-way ANOVA). We found no significant
changes in Tyro3 at any time point examined (Fig. 1E). Pros1was
not significantly increased at any of the time points examined
Figure 1. Gas6, Axl, andMertk, but not Tyro3 or Pros1, mRNA are significantly induced in the lumbar spinal cord during EAE.Aa, EAE clinical scores ofmice used for qRT-PCR analysis. Open circles
represent the scores and days the animalswere removed for RNA isolation and analysis.Ab, Mean clinical scores (CI SEM) of themice on the day of kill; first day sick is considered the first daymice
had a CI 1. Days are counted consecutively thereafter regardless of score. The scores of themice on each day is as follows: first day sick (n 3, CI 1.3 0.17), 4 d sick (n 3, CI 2.3 0.17),
8 d sick (n 9, CI 1.5 0.2), 20 d sick (n 3, CI 0.67 0.17), and naive not shown (n 4, CI 0). Therewas a significant reduction in the clinical scores fromday 4–20with CI ( p
 0.05,
Kruskal Wallis one-way ANOVA). B–F, Fold change reflects EAE value normalized to the value of naive mice (black) shown on the y-axis scale as 1. B,MertkmRNAwas significantly increased in the
spinal cords ofmicewith clinical scores for 4 d ( p
 0.001) and 8 d ( p
 0.05) relative to naive spinal cords. C, Gas6mRNA is significantly increased in spinal cords ofmicewith clinical scores for 8 d
relative to naive ( p
 0.001) and relative to spinal cords with a score for 1 d ( p
 0.01) and 4 d ( p
 0.05). D, Axl is significantly increased at day 8 relative to naive spinal cord and relative to all
other time points ( p
 0.0001). E, F, Tyro3 and Pros1mRNA are not significantly changed relative to naive spinal cord and all time points examined. One-way ANOVAwas used formRNA statistical
comparisons (B–F ).
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(Fig. 1F). Induction of Gas6 and Axl during the transition from
late acute to chronic phase of EAE suggests that these genes may
aid in recovery. Our data are consistent with a report showingAxl
is important for resolution of inflammation (Zago´rska et al.,
2014). Based upon these data that Gas6 and TAM receptors are
induced during EAE and our previous study demonstrating that
administration of GAS6 enhances recovery from cuprizone tox-
icity (Tsiperson et al., 2010), we initiated studies to determine
whether treatment with GAS6 would be beneficial during EAE.
Direct CNS administration of GAS6 is protective during acute
and chronic EAE
After our previous success using intracerebral delivery ofGAS6 in
the cuprizone model, we investigated whether sustained admin-
istration of GAS6 via intracerebroventricular cannula andmicro-
osmotic pump would be beneficial during acute and chronic
EAE. As shown in the schematic in Figure 2A, a cannula was
inserted into the lateral ventricle of female mice. Figure 2B shows
that administration of ACSF plus India ink through a cannula
Figure 2. GAS6 directly administered to the lateral ventricle by cannula/micro-osmotic pump significantly reduced the clinical score of WT mice during acute and chronic EAE. A,
Schematic illustrating cannula implantation into the right lateral ventricle of C57BL/6J mice before induction of EAE. A cannula was inserted into the lateral ventricle of 7-week-old mice
at the coordinates 0.4 mm posterior to bregma, 1.0 mm lateral right, 2.5 mm ventral to skull surface (see Materials and Methods). All mice were monitored for 3 weeks after surgery to
ensure that the mice were healthy before inducing EAE. Six days after the second Ptx injection, the pumpwas inserted under the skin at the scapula and connected to the cannula. B, ACSF
 India ink administered via cannula implanted at our coordinates demonstrates circulation through the ventricles. Arrow indicates blue dye in the ventricle. C, Clinical scores of mice
during acute and chronic EAE. Mean clinical scores of ACSF-treatedmice (n 10) and GAS6-treatedmice (n 15). #p 0.01; *p 0.05, Mann–Whitney U test. There was no difference
in the day of onset of clinical scores in the two groups of mice.
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Figure 3. GAS6 treatment significantly reduced the number of SMI32-damaged axons, but did not significantly reduce the relative Iba1 inflammatory scores relative to ACSF-treatedmice.
Aa–Ax, Two representative sections fromACSF-treated (n 4) and GAS6-treated (n 7)mice are depicted. All bars are 50m.Aa–Ad, Iba1 immunostaining quantified inB. GAS6-treatedmice
trended toward fewer Iba1-activatedmacrophages/microglia; however, the relative inflammatory scoreswere not significantly different ( p 0.05,Mann–WhitneyU test). The extent of Iba1
stainingwas reflected in the clinical score of eachmouse such thatmicewith lower clinical scores had less Iba1 staining/spinal cord.Aa,Ab, ACSF-treatedmice.Ac,Ad, GAS6-treatedmice.Ae–Ap,
SMI31 immunostaining. Aq–Ax, SMI32 immunostaining. Ae–Ax, GAS6-treated mice have more SMI31 axons (Ag, Ah, Ak, Al ), less neuronal cell body staining in gray matter (Ao, Ap), and
significantly fewer SMI32 axonal swellings (As, At, Aw, Ax) than ACSF-treated mice (Ai, Aj, Am, An, Aq, Ar, Au, Av). Asterisk in Ae–Ah denote ventral spinal cord region shown at higher
magnification inAi–Al. Note the presence of SMI31 immunoreactivity in the cell body of ACSF neuronswithin graymatter (Am,An;400) and clear SMI31 neurons in GAS6-treatedmice (Ao,
Ap; arrows). Arrows in Au–Ax indicate SMI32 swellings in the ventral spinal cord. B, Quantification of Iba1 glia in lumbar spinal cord; the mean scores for the two (Figure legend continues.)
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placed at the designated coordinates illustrates that the dye effi-
ciently reached the lateral and third ventricles. GAS6-loaded (4
g/ml) or ACSF-loaded pumpswere attached to the cannulae 6 d
after the second Ptx injection and mice were examined after
25–28 d of treatment; therefore, all histological analyses were
performed on mice during chronic EAE.
As shown in Figure 2C, compared with the ACSF-treated
mice, GAS6 treatment did not alter the day of onset of disease or
the initial clinical course up to day 15. From days 16–30, there
was a statistically significant decrease in the clinical scores of the
GAS6-treated mice relative to the ACSF-treated mice represent-
ing peak disease (p 
 0.05) and throughout the chronic phase
(p
 0.01, Mann–Whitney U test).
Consistent with a significant difference in the clinical scores
during chronic EAE, we observed a decrease in the overall num-
ber of Iba1 cells/spinal cord in theGAS6-treatedmice relative to
the ACSF-treated WT mice (Fig. 3A,B). Figure 3A shows repre-
sentative lumbar spinal cord sections from two ACSF-treated
(Fig. 3Aa,Ab) and twoGAS6-treated (Fig. 3Ac,Ad) immuostained
for Iba1. Figure 3B shows themean Iba1 scores for the two groups
of mice based upon a 1–4 scale. The mean Iba1 inflammatory
score of the ACSF-treated mice was higher but was not signifi-
cantly different, because one ACSF-treated mouse had minimal
Iba1 staining and a GAS6-treated mice had a mean Iba1 score of
2.5 (p  0.05; Mann–Whitney U test). In a second study with
independent groups of GAS6- and ACSF-treated mice, there
was also no significant difference in the Iba1 inflammatory
score and pooling the data from the two experiments was also
not significant, indicating mouse to mouse variability in
monocyte/macrophage/microglial activation at the chronic
endpoint. Quantification of T-cell infiltration by CD3 immu-
nostaining did not demonstrate a significant difference in the
relative scores (data not shown).
Immunohistochemical staining using mAbs specific for phospho-
neurofilament (SMI31) and non-phospho-neurofilament (SMI32)
proteinandlightmicroscopyshowed that therewas significantly less
axonal damage in the lumbar spinal cord of GAS6-treated mice
relative to the ACSF-treatedmice (Fig. 3Ae–Ax). To confirm that
increased axonal swelling coincided with reduced axonal integ-
rity, we stained spinal cord sections with SMI31, an antibody that
recognizes phosphorylated neurofilament protein in healthy ax-
ons. Figure 3, Ae–Al, shows staining for SMI31 at low (Fig. 3Ae–
Ah; 5) and high magnification (Fig. 3Ai–Al; 100 objective).
Cross-sections of the lumbar spinal cord show less SMI31 immu-
noreactivity in the white matter of the ventral spinal cord of ACSF-
treated mice (Fig. 3Ae,Af) relative GAS6-treated mice (Fig. 3Ag,Ah;
5 objective). Two representative mice from each group are de-
picted (Fig. 3Ae–Ah; asterisk in each panel illustrates the ventral
white matter region shown at highmagnification in Fig. 3Ai–Al).
The presence of SMI31 phosphorylated neurofilament pro-
tein in the neuronal cell body is as an indicator of neuronal cell
body injury. Figure 3, Am–Ap, shows that there are significantly
more SMI31motor neuron cell bodies within the graymatter of
the ACSF-treated mice, 8.56 3.45 (Fig. 3Am,An; arrows, 40),
than in the GAS6-treatedmice, 1.67 0.88 (p 0.033, Student’s
t test; Fig. 3Ao,Ap). In contrast to the SMI31 axonal immuno-
staining, we observed that ACSF-treated mice had more3 mi-
cron SMI32 axonal swellings in the ventral region of the spinal
cord (Fig. 3Aq,Ar,Au,Av) than the GAS6-treated mice (Fig.
3As,At,Aw,Ax). The arrows in Figure 3, Au–Ax, refer to 3 mi-
cron swellings observed at higher magnification (20). We
quantified the number of SMI32 axonal swellings in multiple
20 fields for the left and the right ventral region of white matter
from ACSF- and GAS6 treated mice. As demonstrated in Figure
3C, we found significantly fewer SMI32 swellings in the GAS6-
treated mice (n  7) relative to the ACSF-treated mice (n  4)
(p 0.034, Student’s t test). Additional analysis of APP axonal
staining showed no significant increase in APP spheroids in the
ventral spinal cord of the two groups ofmice (data not shown). It
is known that APP immunostaining within axons is indicative of
fast axonal transport defects is transient and best observed during
early stages of axonal damage, often not coinciding with SMI32
swellings (Soulika et al., 2009).
While quantifying the number of SMI32 swellings, we de-
tected a large number of dystrophic (10 m) SMI32 axonal
spheroids (Fig. 4Aa, arrow). To quantify those specifically and
to quantify demyelination, we performed immunofluorescent
staining on the treated spinal cords. In Figure 4A, we show
double-label immunofluorescent staining of spinal cord sections
from three different ACSF-treated (Fig. 4Aa,Ae,Ai) and GAS6-
treated (Fig. 4Ac,Ag,Ak)mice with antibodies to SMI32 (red) and
MBP (green) by fluorescent microscopy (10). The asterisk re-
fers to the area of 60 magnification in Figure 4, Ab,Af,Aj and
Ad,Ah,Al. Using Volocity image analysis software (PerkinElmer),
we quantified the number and size of SMI32 swellings from
40 images spanning the ventral lumbar spinal cord. We found
significantly more axonal swellings 3 m (p 
 0.05) and dys-
trophic axons10m(p 0.012) inACSF-treatedmice (n 7)
relative to GAS6-treated mice (n 10) (Fig. 4B). Next, we quan-
tified the relative amount of MBP immunoreactivity for the 2
treated groups using a 1–4 scale (Fig. 4C). We observed signifi-
cantly more MBP immunoreactivity in the ventral region of the
lumbar spinal cord of GAS6-treated mice (n  10) relative to
ACSF-treated mice (n  7), p  0.02 (Fig. 4C). In addition, the
extent of demyelination was calculated as a percentage of the
demyelinated area relative to the total white matter area within
the lumbar spinal cord as described in Materials and Methods.
We found significantly less demyelination in the GAS6-treated
mice (n  10) than in control ACSF-treated mice (n  7; p 
0.012, Student’s t test; Fig. 4D). Our data indicate that there was
less demyelination and/or enhanced remyelination in spinal
cords treated with GAS6 relative to controls.
IFN administered by subcutaneous injection to GAS6-
treated mice fails to further reduce the clinical score of GAS6-
treated mice
In the Prevention of Relapses and Disability by Interferon -1a
Subcutaneously in Multiple Sclerosis (PRISMS) study of 1998,
IFN was found to be therapeutic for delaying the time between
episodes and is now used by individuals with relapsing remitting
MS. In the context of ourGAS6 regimen, we investigatedwhether
a subcutaneous IFN injection (Betaseron; Bayer) on alternate
days commencing 7 d after the second Ptx injection would fur-
ther reduce the clinical scores of mice receiving GAS6 and ACSF.
4
(Figure legend continued.) groups of mice based upon a 1–4 scale: Iba1 cells were scored on
a 1–4 inflammatory scale where 1mild inflammation at lesions, 2moderate inflamma-
tion at lesions, 3 severe inflammation at lesions, and 4 very severe inflammation involv-
ing 50% or more of the spinal cord (Tsiperson et al., 2013; Mann–Whitney U, p 0.05). The
mean relative Iba1 inflammatory score of the ACSF-treated mice (n 4) was 2.75 0.60 the
mean score for the GAS6-treatedmice (n 7) was 1.86 0.21 (p 0.05). C, Graph of themean
number of SMI32 axonal swellings (3m) in multiple 20 fields for the left and the right
ventral regionof the lumbar spinal cord of ACSF andACSFGas6-treatedmice. The SMI32 swell-
ings for the ACSF-treatedmice (n 4)were 33.2 4.6 and 18.3 3.6 for the GAS6-treatedmice
(n 7), p 0.034.
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GAS6-treated mice (4 g/ml) had significantly reduced clinical
scores relative to the ACSF-treated cohort. As demonstrated in
Figure 5A, injection of IFN alone delayed the onset of EAE by
3 d. When GAS6  IFN treatment was compared with GAS6-
only treatment, the data showed that GAS6 was more effective at
reducing clinical scores. The graph in Figure 5B demonstrates
that, within the groups of mice tested, the IFN  GAS6-
treatment did not significantly reduce axonal dystrophy. This
study shows that, although IFN delayed the start of EAE, it
could not protect against the axonal damage ultimately incurred
during chronic disease and GAS6  IFN did not result in a
synergistic response. Because GAS6 affords better protection
against axonal damage, no further IFN studies were explored.
Deletion ofGas6 enhances inflammation in spinal cord,
increases clinical scores, and delays recovery from EAE
Our current studies indicate that GAS6 is beneficial during EAE
and predict that loss of GAS6 signaling would be detrimental
during EAE. To determine whether deletion ofGas6would exac-
erbate disease progression, WT and Gas6/ mice were sensi-
tized with MOG peptide and monitored over the course of EAE.
Figure 6A shows a graph compiled from six independent EAE
experiments. There was no difference in the mean day of onset of
clinical scores for the two groups of mice; therefore, the day of
onset was normalized to day 10 for comparison. In this compos-
ite graph, there was a significant difference in clinical scores be-
tween WT and Gas6/ mice beginning 4 d after the onset of
Figure 4. GAS6 treatment results in significantly less demyelination and fewer damaged axons.A, Lumbar spinal cord sections fromACSF- (Aa,Ab,Ae,Af,Ai,Aj) and GAS6-treatedmice (Ac,Ad,
Ag, Ah, Ak, Al) were stained for nonphosphorylated neurofilament protein usingmAb SMI32 (red) and for MBP (green) and examined by fluorescencemicroscopy at both 20 and 60. Arrow
denotes axonal spheroid (Ab) and axonal swellings (Ad).B, Volocity quantification of SMI32 axonal swellings3mand dystrophic axons10m. The number of SMI32 axonal swellings
3mwas significantly lower inGAS6-treatedmice 19.983.010 (n10) versusACSF-treated37.488.907 (n7),p
0.05 (Student’s t test); similarly, thenumber of SMI32 axons10
m was significantly lower in GAS6-treated mice 2.380 0.4982 (n 10) than in ACSF-treated mice 9.658 3.017 (n 7) ( p 0.0123, Student’s t test). C, Quantification of relative
demyelination score by MBP immunoreactivity: a score of 0 is the equivalent of MBP immunoreactivity observed in naive ventral spinal cord; we did not observe this in any of our treated sections.
A score of 1mild demyelination, 2moderate demyelination, 3 severe demyelination, and 4 very severe involving greater that 50% of white matter. Before quantification, slide identity
was masked to the reviewer and at least 3 sections of lumbar spinal cord/specimen were assessed by two individuals. Significantly more MBP immunoreactivity was observed in the ventral region
of lumbar spinal cord of GAS6-treatedmice 1.8 0.19 (n 10) relative to ACSF-treatedmice 2.7 0.32 (n 7) ( p 0.02,Mann–WhitneyU test).D, The extent of demyelinationwas calculated
asapercentageof thedemyelinatedarea relative to thepercentageof the totalwhitematter areawithin thedorsal, ventral and lateral regions. Themeanpercentageofdemyelination for theACSF
mice was 9.658 3.02 (n 7) and the mean percentage of demyelination for theGAS6 mice was 2.380 0.50 (n 10) ( p 0.012, Student’s t test).
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clinical signs and continuing through the disease course (Mann–
Whitney U test). Among the six independent time courses, the
first day inwhichwe observed a significant difference in themean
clinical scores between the Gas6/ and WT mice varied by
1–2 d, however, we consistently observed that the chronic
course of disease was higher in the sensitized Gas6/ mice. All
mice included in the study had a clinical course. We found that
56.6% of Gas6/ mice had hindlimb paralysis and scores 3,
whereas 31% of WT mice had scores of 3 during the course of
disease. The percentage of mice having hindlimb paralysis and
forelimb weakness/paralysis [Clinical Score/Clinical Index
(CI)  3.5] was 24% for Gas6/ mice and 2.4% for the WT
mice, indicating that there is a larger cohort of Gas6/ animals
that experience a more severe course than the WTmice. Because
animals were removed at different times during the study for
histologic/pathologic and molecular analyses, there were 20 WT
and 24 Gas6/mice remaining on day 25.
Immunocytochemical staining for Iba1 and CD3 within the
spinal cord were evaluated for increased macrophage/microglia
and T-cell infiltration, respectively (Fig. 6B,C). For this study,
the mice were killed 20 d after the first Ptx injection and all mice
in both groups hadmean clinical scores for 8–12 d. TheGas6/
mice (n 6) had a mean score of 2.5 and the mean of WT mice
(n 7) was 1.3; p 0.005 (Mann–WhitneyU test). The graph in
Figure 6Ba and the staining in Figure 6, Cb and Cf, show that
there was a significant increase in Iba1 glia in Gas6/ mice
relative to WT as assessed by the scale in Materials and Methods.
The mean Iba1 inflammatory score in spinal cord was signifi-
cantly higher in theGas6/mice (3.33 0.22, n 6) relative to
theWTmice (p 0.0041,Mann–WhitneyU test).We quantified
the overall CD3 immunoreactivity (Fig 6Cc,g) on the same in-
flammatory scale used to quantify Iba1 and found no significant
difference in the two groups at this time point (p  0.05; Fig.
6Bb). In addition, we quantified the number of CD3-
immunopositive cells within lesions and found no significant
difference between Gas6/ and WT mice (data not shown).
Quantification of SMI32 swellings and the representative im-
munostaining is depicted in Figure 6, Bc,Cd,Ch. We found that
there were significantly more axonal swellings in lumbar spinal
cords of Gas6/mice relative to WT mice (p
 0.05, Student’s
t test). Finally, byMBP immunofluorescent staining andmicros-
copy, we quantified the percentage demyelination in 4 images
(Fig. 6Bd,D). We found Gas6/ mice experienced significantly
more demyelination thanWTmice at this time point during EAE
(p 0.018, Student’s t test).
Gas6/mice have increased expression of proinflammatory
molecules during acute EAE
The significant increase in the number of Iba1 inflammatory
cells in the Gas6/ mice led us to examine additional mice by
qRT-PCR to identify proinflammatory molecules that might
contribute to the more severe clinical course in the Gas6/
mice. Proinflammatory cytokine and chemokine molecules are
expressed in and secreted by multiple CNS cell types, including
astrocytes and microglia, as well as infiltrating T cells and mac-
rophages. Figure 7A shows the clinical course for the 2 cohorts
examined specifically for this analysis. RNA was isolated from
lumbar spinal cord of mice having clinical scores for 8 d because
we typically found that WT and Gas6/ scores diverge and be-
come significantly different at this time point. On the day of
killing, the average score of the WT mice (n  8) was 1.5  0.2
versus 2.5  0.15 for the Gas6/ mice (n  9) (p  0.002).
Consistent with the graph showing the combined scores illus-
trated in Figure 6A, clinical scores in the WT mice began to de-
cline after4 consecutive days, whereas the clinical scores of the
Gas6/mice remained elevated.
Proinflammatory cytokines/chemokines andothermarkers of
inflammation were elevated in the two groups of mice. Figure 7B
shows there was a significant increase in TNF, IL-6, CD68, and
IL-17 in Gas6/ spinal cord relative to WT spinal cord. Exami-
nation of T-cell-associated cytokines IL-2, IL-17, and IFN
showed that the Th17 proinflammatory cytokine IL-17 was sig-
nificantly increased in theGas6-treatedmice (p 0.02); IL-2 and
IFN were increased2-fold, but significance was not obtained.
We found that the chemokines RANTES (CCL5) and MCP-1
(CCL2) were elevated2-fold in the Gas6/ mice, but signifi-
cance was not obtained. The chemokine CCL3/MIP1 was sig-
nificantly increased in the WT spinal cord relative to Gas6/,
Figure 5. Subcutaneous (subQ) IFN injection was not beneficial in reducing the clinical
scores during acute and chronic EAE inmice treatedwithACSF or GAS6.A,Micewere given subQ
injections of human IFN (3 10 4 units, Betaseron) on alternate days commencing 7 d after
the second Ptx injection. The groups consisted of WT mice treated with IFN ACSF (open
circle,n 4), IFNGAS6 (closed square,n 5),ACSF (inverted closed triangle,n 10),
and GAS6 (open triangle, n  15). B, Quantification of SMI32 axonal swelling in the
ventral spinal cord of treated mice. IFN treatment did not result in a significant reduction of
SMI32 swellings when administered with or without GAS6 ICV.
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Figure 6. Gas6/ mice have a more severe disease course than WT mice during EAE. A, Six pooled experiments illustrate higher clinical scores during peak acute disease and recovery in
Gas6/mice compared withWTmice. There was no difference in the mean day of disease onset in Gas6/ (n 54) andWT (n 42) mice; data were normalized to day 10, the first day the
mice had a clinical score. Significant differences in the composite scores begin at peak disease and continue into the chronic phase. *p 0.05. B, Quantification of immunohistochemical staining
in C and immunofluorescent staining in D. Comparison of Gas6/ and WT cohorts were analyzed from sensitized mice within the same study. Ba, At day 20 after (Figure legend continues.)
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which was unexpected given that this proinflammatory chemo-
kine is associated with the acute response, where it can induce the
synthesis and release of other proinflammatory cytokines includ-
ing IL-6, TNF, and IL-1.
We examined IL-4, IL-13, IL-10, and TGF- expression to
determine whether there was differential expression of these cy-
tokines described as anti-inflammatory in the context of EAE.
IL-4 is predominantly expressed by a subpopulation of activated
Th2 cells and IL-13 is expressed by lymphocytes. IL-10 is pre-
dominantly synthesized by monocytes, Th2 cells, and
CD4CD25Foxp3 regulatory T cells. Although we did not
observe a significant change in the expression of these anti-
inflammatory cytokines in the two groups of mice, we did ob-
serve a trend toward less IL-13mRNA in theGas6/ spinal cord.
IL-13 is known to inhibit mRNA expression of several cytokines,
including TNF, MCP-1, IL-1, and TGF- (Zhu et al., 2010),
which is consistent with our data showing either a trend toward
or a significant increase in TNF,MCP-1, and TGF-mRNA in
theGas6/ group of mice. TGF-was significantly increased in
Gas6/ spinal cord. TGF-was shown to increase CCL2/MCP1
production and to activate CCR2 to enhance cell motility and
alter actin cytoskeletal dynamics (Lee et al., 2009). However, the
role of TGF- in EAE is complex, because it was initially de-
scribed as protective, but more recently was shown to be impor-
tant in the initiation of EAE primarily through its role in Th17
differentiation (Kuruvilla et al., 1991; Bettelli et al., 2006); our
data agree with the latter because we see a significant increase in
TGF- and IL-17 mRNA. CD68 and CCR2, expressed in micro-
glia/macrophages, were significantly increased inGas6/ spinal
cord, which is consistent with the increased TGF- in Gas6/
mice. Expression of the fractalkine receptor CXC3R1 was not
altered.
Upregulation of suppressor of cytokine signaling-1 (SOCS-1)
and SOCS-3 mRNA is induced by several cytokines including
IL-6 and IFN. We observed a significant increase in SOCS-3
mRNA in Gas6/ spinal cord (p 0.03) that correlated with
the significant increase in IL-6mRNA expression. SOCS-1 was
also elevated in Gas6/ spinal cord, but significance was not
achieved.
We addressed whether Pros1 expression might compensate
for the loss of Gas6 and investigated whether Axl, Tyro3, and
Mertk Mertk might be altered because there is precedence for
TGF1 inducingAxl expression (Bauer et al., 2012) andwe found
TGF1 to be increased inGas6/ spinal cord. In addition,Tyro3
expression is increased in the mature CNS, where its expression
parallels synaptogenesis, suggesting thatTyro3 expressionmay be
altered in Gas6/ spinal cord during EAE. Figure 7B shows that
there was no change in Pros1, Axl, orMertkmRNA in spinal cord
of the two groups. In contrast, Tyro3 was significantly decreased
inGas6/ spinal cord relative toWT spinal cord (p
 0.05). The
observed decrease in Tyro3 expression is consistent with the ob-
served axonal damage and reduced MBP immunostaining de-
tected in the Gas6/ spinal cord.
All three TAM receptors andGas6 are expressed in whitemat-
ter during myelination (Prieto et al., 2000; Shankar et al., 2006)
andGas6 has been shown to play important roles in oligodendro-
cyte survival, maturation, andmyelination. This led us to explore
whether there were EAE-induced changes in gene expression in
twoessential oligodendrocyte transcription factors,Olig2andSox10,
both expressed throughout oligodendrocyte development andmat-
uration, and the early oligodendrocyte receptor PDGFR. The
HMGdomain transcription factor Sox10 is expressed immediately
after oligodendrocyte specification and is known to regulate
PDGFR and MBP expression (Stolt et al., 2002; Finzsch et al.,
2008). As depicted in Figure 7, Olig2, Sox10, and PDGFR were
significantly reduced in Gas6/ lumbar spinal cord relative to
WT mice (p 
 0.05), which is consistent with demyelination in
Gas6/ spinal cord mice relative to WT spinal cord (Fig. 6D).
Gas6/mice have significantly more macrophages
infiltrating the spinal cord thanWT spinal cords during acute
EAE
The significant increase in Iba1 microglia/macrophages and
the increase in inflammatory cytokine gene expression in the
Gas6/ and WT spinal cords during EAE led us to examine the
populations of potentially inflammatory immune cells by flow
cytometry. We chose to examine the peak of disease (3–4 d sick)
because this is when the largest number of immune cells infiltrat-
ing the CNS are present.We found a significant, 3.4-fold increase
in CD11b CD45hi CD68 macrophages in Gas6/ spinal
cord relative to WT. (Fig. 8A,C; p  0.0005, Student’s t test).
Activated T cells, CD4 CD25 CD44, were marginally in-
creased in Gas6/ spinal cord relative to WT spinal cord but
were not significantly higher (Fig. 8B,C); the total number of
CD4 cells was also similar between the two cohorts. In addition,
we examined the percentages of microglia, B cells, Tregs, and
Th17 T cells and found no significant differences in the Gas6/
andWT spinal cords at this time point. The clinical scores of the
Gas6/mice were higher the day of killing, but not significantly
different between Gas6/ (CI  2.313) and WT (CI  1.714)
(p 0.065, Mann–Whitney U test). These results are consistent
with our data in Figures 6 and 7.
Our combined data show that loss of Gas6 signaling enhances
inflammation, increases axonal damage and demyelination, and
impairs recovery during EAE. Targeted Gas6 delivery to the CNS
of WT mice during EAE reduces the clinical course of EAE, Iba1
macrophage/microglia expression, and SMI32 axonal swelling
and demyelination.
Discussion
Because a preponderance of studies show an important role for
GAS6 in the regulation of inflammation and because our own in
vitro and in vivo studies showed that GAS6 enhanced oligoden-
drocyte survival andmyelination (Shankar et al., 2003; Shankar et
al., 2006; Tsiperson et al., 2010; O’Guin et al., 2014), we tested the
hypothesis that GAS6 would be beneficial in an autoinflamma-
tory model of multiple sclerosis, EAE. In the context of the EAE
inflammatory environment, we posited that GAS6/TAM signal-
ing is influential in regulating inflammatory gene expression and
maintaining axonal integrity and myelination in the CNS.
4
(Figure legend continued.) sensitization, there wasmore extensive Iba1 immunostaining based
on our relative Iba1 inflammatory scoring in the lumbar spinal cords of Gas6/ mice
(3.33 0.22, p 6) relative toWTmice (2.04 0.23, p 7) (p 0.004,Mann–WhitneyU).
Bb, CD3 staining was assessed according to the same parameters discussed for the Iba1
inflammatory scoring system. We found that CD3 inflammatory score was not significantly
increased in Gas6/ spinal cords 2.75 0.34 (n 6) different relative to WT spinal cords
2.0 0.28 (n 7) ( p 0.05, Mann–Whitney U). Bc, The number of SMI32 swellings was
significantly higher in Gas6/ 33.79 5.49 mice relative to WT mice 19.54 3.72 ( p

0.05, Student’s t test). Bd, The percentage demyelination was significantly increased in
Gas6/ spinal cords 14.54 3.51% relative toWT spinal cords 4.825 1.28% ( p 0.018,
Student’s t test). C, H&E (Ca, Ce), Iba1 (Cb, Cf), CD3 (Cc, Cg), and SMI32 (Cd, Ch) staining ofWT
and Gas6/ representative spinal cord sections. D, IF staining of representative WT (Fa, Fb)
and Gas6/ (Fc, Fd) mice. Fa–Fd, Blue DAPI (Fb, Fd); greenMBP (Fb, Fd), a merge/
composite of MBP and DAPI. White dots trace areas of demyelination.
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Figure 7. qRT-PCR demonstrates that, relative to WT mice, Gas6/ mice have increased cytokine/chemokine mRNA expression in spinal cord and reduced expression of oligodendrocyte
markers during EAE.A, Clinical course ofGas6/ andWTmice sensitizedwithMOG35-55 peptide. Allmicewith scores1.0were killed after having scores for 8 d. On the day of killing, the average
score of theWTmice (n 8)was 1.5 0.2 versus 2.5 0.15 for the Gas6/mice (n 9) ( p 0.002).B, qRT-PCR shows thatGas6/mice have increased inflammatory cytokine expression
and decreased expression of oligodendrocyte lineage markers. *p 0.05; **p 0.01; ***p 0.001.
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Figure 8. Flow cytometry analysis demonstrates an increase in CD11b CD45hi CD68macrophages in Gas6/ spinal cord/mice during EAE. A, C, Macrophages (CD11b CD68 CD45hi
CD4B220), expressedas thepercentageof single cells CD11bCD4B220,were assessedby flowcytometry in cells isolated fromthe spinal cordofGas6/andWTmiceduringacute EAE,
mice had scores for 3–4 d.WTmice had 5.1 0.5%macrophages in the spinal cord, whereasGas6/mice displayed a significantly higher percentage ofmacrophages (Figure legend continues.)
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We report that, in WT spinal cords, Mertk expression was
significantly increased in mice with clinical scores for 4 and 8
days, corresponding to acute disease, a period when activated
inflammatory cells infiltrate the CNS and contribute to glial ac-
tivation. Gas6 and AxlmRNA expression were both significantly
increased at day 8 and Axl was elevated throughout the EAE
course. Pros1 and Tyro3mRNA expression were not significantly
altered in WT spinal cords during EAE.
Our study demonstrates that continual intracerebroventricu-
lar GAS6 delivery by micro-osmotic pump was beneficial. Rela-
tive to the ACSF-treated mice, clinical scores were reduced
during peak acute and chronic disease. Although a significant
difference in Iba1 staining was not observed during the chronic
phase of EAE after GAS6 treatment, we did observe significantly
fewer SMI32 axonal swellings and spheroids and more robust
SMI31 axons in the spinal cord ofGAS6-treatedmice relative to
the ACSF-treated mice, indicative of reduced axonal damage.
Further, more robust MBP immunoreactivity, an indicator of
myelination, was observed in the spinal cord of GAS6-treated
mice consistent with healthier SMI31SMI32 axons and pro-
tected myelin ensheathment. GAS6-mediated axonal protection
is likely the result of both its anti-inflammatory properties and its
known role as a neurotrophic factor (Allen et al., 1999; Prieto et
al., 2000; Funakoshi et al., 2002; Yagami et al., 2002; Gely-Pernot
et al., 2012).
Although the mechanism of IFN action is not well defined,
IFN is administered to individuals with MS to reduce relapses.
IFN and IFN signal through IFNR1/2 tomaintain homeostasis
and to reduce inflammation. TLR activation of IFNR1/2 by IFN
increases TAM signaling resulting in AXL binding to IFNR1/2
and reduced inflammation (Rothlin et al., 2007). IFN exerts
positive feedback over the induction of IFN genes (Marie´ et al.,
1998). When we compared GAS6 treatment alone with GAS6
IFN, we determined that GAS6 was more potent and GAS6 
IFN did not result in a synergistic response nor significantly
reduce axonal dystrophy; no further IFN studies were pursued.
It is possible that the simultaneous addition of GAS6  IFN
altered availability and homoeostasis of the TAM receptors with
fewer membrane-bound TAMs available for inhibiting the in-
flammatory response. This analysis is beyond the scope of the
current study and will require further extensive evaluation.
To further corroborate the importance of GAS6 in maintain-
ing the integrity of the CNS, we show that Gas6/ mice were
more severely compromised during EAE.Unlike the tripleTyro3/
Axl/Mertk knock-outmice (Lu and Lemke, 2001), naiveGas6/
mice are not severely immunocompromised. However, during
EAE,Gas6/mice had amore severe peak and chronic phase of
disease, with delayed recovery, increased Iba1 glia, increased
expression of proinflammatory molecules, decreased expression
of oligodendrocyte markers, and increased numbers of axonal
swellings.
Relative to WT mice, we observed significantly higher CD68,
IL-17, IL-6, TNF, and SOCS3 and less MIP-1 (CCL3) mRNA
expression in lumbar spinal cord ofGas6/mice having clinical
scores for 8 d. CD68 is expressed on the cell surface ofmonocytes,
macrophages, and microglia and its increased mRNA expression
is consistent with the increase in relative amount of Iba1 im-
munostaining in theGas6/ spinal cords. Using flow cytometry
analysis, we determined that there was a significant increase in
CD11b CD45hi CD68 macrophages during acute EAE in
Gas6/spinal cords, which corroborates the increase in Iba1
cells that we observed in tissue sections. Furthermore, we did not
find significant differences in activated T-cells, Tregs, Th17 cells,
B cells, ormicroglia betweenWTandGas6/mice at 3–4 d sick.
Th17 cells infiltrate the brain before the development of clin-
ical symptoms of EAE, resulting in activated microglia and in-
creased IL-17, TNF, IL-6, and IL-1 proinflammatory cytokine
production and increased CNS inflammation (Murphy et al.,
2010). Several proinflammatory cytokines, including IL-6,
TNF, andMIP-1, are expressed in the CNS and are secreted by
microglia and/or astrocytes as well as macrophages. IL-6 activa-
tion can activate Janus kinases (JAKs)/ STAT/MAPK pathways,
and alter gene expression (Taga and Kishimoto, 1997; VanWag-
oner et al., 1999), whereas IL-6 can suppress TNF, which itself
can promote inflammation or remyelination depending upon
which receptor (TNFR1 or TNFR2) is activated (Arnett et al.,
2001). Gas6/ mice have significantly increased amounts of
both IL-6 and TNF mRNA in lumbar spinal cords relative to
sensitized WT spinal cords, indicating that these cytokines con-
tribute to the increasedCNS injury and higher clinical scores seen
in Gas6-deficient mice.
Signaling from Gas6 to TAM receptors dampens inflamma-
tion, reduces expression, and enhances phagocytosis in macro-
phages/microglia (Grommes et al., 2008; Alciato et al., 2010). M2
noninflammatory macrophages are associated with improve-
ment of neurological impairment during EAE (Denney et al.,
2012).M2cmacrophages expressMERTK andGAS6 in a positive
feedback loop that promotes debris clearance and reduces in-
flammation; IL-4, IL-10, and glucocorticoids increase Gas6 pro-
duction (Zizzo et al., 2012). In addition, astrocytes were shown to
mediate synapse elimination by signaling through the MERTK
and MEGF10 pathways, demonstrating a role for MERTK and
PROS1 in phagocytic synapse remodeling (Chung et al., 2013). In
our EAE model, Pros1 was not transcriptionally upregulated in
the CNS, but PROS1 signaling cannot be ruled out. However, we
previously demonstrated that deletion of Axl results in increased
myelin debris and reduced myelination during cuprizone intox-
ication and EAE. This is consistent with other TAMmembers in
addition toMERTK/PROS1 participating in debris clearance and
repair (Seitz et al., 2007; Hoehn et al., 2008; Weinger et al., 2011;
Zago´rska et al., 2014).
We report a significant reduction in Olig2, Sox10, and
PDGFR expression inGas6/ spinal cord relative toWT spinal
cord that is consistent with studies showing that GAS6 functions
in oligodendrocyte survival andmaturation (Shankar et al., 2003;
Shankar et al., 2006; Binder et al., 2008; Tsiperson et al., 2010;
Binder et al., 2011; O’Guin et al., 2014). Olig2 is important for the
differentiation of neural progenitor cells into the oligodendro-
cyte lineage (Copray et al., 2006; Ligon et al., 2006) because Olig2
disruption results in a lack of NG2 OPCs and in decreased
numbers of oligodendrocytes in the spinal cord (Lu et al., 2002;
Ligon et al., 2006). Sox10 promotes terminal oligodendrocyte
4
(Figure legend continued.) 17.6 2.5% (p 0.0005, Student’s t test). B, C, Activated T cells
(CD4CD44 CD25) are expressed as a percentage of total CD4. Activated T cellswere not
significantly higher in Gas6/ spinal cord/mice 17.5 3.7% compared withWT spinal cord
13.12.6%( p0.05, Student’s t test).C, Quantification of thepercentages of populations of
infiltrating and resident immune cells in the CNS of Gas6/ and WT mice. Microglia are
expressedaspercentageof CD11bCD4B220 single cells identified as CD45 intermediate.
B cells are expressed as the percentage of single cells defined as CD45R/B220 CD25 CD4
CD11c CD11b. Activated T cells (CD4 CD44 CD25) are expressed as a percentage of
total CD4 single cells. Th17 and Tregs are expressed as the percentage of activated T cells that
are RORt and Foxp3, respectively.With the exception ofmacrophages, the p-value for all
of the examined populations was p 0.05.
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differentiation and deletion of Sox10 disrupts oligodendrocyte
differentiation (Stolt et al., 2002). Further, Sox10 influences sur-
vival and migration of oligodendrocyte precursors in the spinal
cord by regulating PDGFR and MBP expression (Finzsch et al.,
2008). TYRO3 expression increases in the CNS during postnatal
development (Prieto et al., 2000) and Tyro3 mRNA transcripts
increase as oligodendrocytes mature (Cahoy et al., 2008). We
found that Tyro3 transcripts were significantly reduced in spinal
cord ofGas6/mice with scores for 8 consecutive days, suggest-
ing that diminished axonal integrity and remyelination in the
damaged CNS results in reduced Tyro3 mRNA expression. Al-
though our data support the hypothesis that GAS6 signaling is an
important mediator of protective effects in the CNS during EAE,
future studies creating GAS6/receptor double knock-out mice
will address the relative contributions of each receptor to CNS
protection and elucidate to what degree PROS1 and other TAM
receptors are compensating.
Our data provide compelling support for a beneficial effect of
GAS6 during an inflammatorymodel ofMS, EAE. There is build-
ing evidence that GAS6/TAM signaling is altered in human dis-
ease, including MS (Weinger et al., 2009; Sainaghi et al., 2013)
and other autoimmune diseases such as rheumatoid arthritis,
inflammatory bowel disease, and lupus (Bassyouni et al., 2014;
Rothlin et al., 2014; Zhu et al., 2014). In addition, MERTK, lo-
cated on human chromosome 2q14.1, has been identified as a
gene associated with a possible genetic risk factor forMS (Sawcer
and Hellenthal, 2011; Raj et al., 2014). SevenMERTK SNPs (p

0.05) were suggestive of an association withMS (Ma et al., 2011),
further implicating a role for TAM receptors in autoimmune
disease and specifically MS.
Currently approved treatments for multiple sclerosis are fo-
cused on disruption of the inflammatory component of the dis-
ease; however, GAS6 has the ability to influence other aspects of
the disease pathogenesis as well. We demonstrate that GAS6 sig-
naling not only dampens inflammation and proinflammatory
gene expression, but also influences OPC maturation, enhances
myelination, and preserves axonal integrity, functions that IFN
cannot achieve. Although anOmmaya reservoir could be used for
intracerebroventricular delivery of GAS6, it is likely not an ideal
option for clinical treatment of demyelinating disease. However,
becauseGAS6 is a soluble ligand for the TAM receptors, synthetic
small-molecule or biologic agonists for these receptorsmay be an
attractive candidate for anti-inflammatory, neuroprotective, and
promyelinating therapies.
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